Novel Therapy for Pediatric Leukemia Patients with NUP98 Translocations |
The Regents of the University of Michigan / Jolanta Grembecka, PhD |
Reach Grants |
2022 |
Michigan |
Preclinical Development of a First-in-Class PCNA Inhibitor for Treating Neuroblastoma |
City of Hope National Medical Center / Linda Malkas, PhD |
Reach Grants |
2019 |
California |
Optimization of Drug Efflux and Brain Clearance to Improve CED of Targeted Therapy to H3K27M DMG |
Mayo Clinic / David Daniels, MD/PhD |
Reach Grants |
2021 |
Minnesota |
Generation of CMV-specific CD19 CAR T cells Using Cytokine Capture Followed by Lentiviral Transduction and Expansion |
Research Institute at Nationwide Children's Hospital / Margaret Lamb, MD |
Reach Grants |
2019 |
Ohio |
Novel Genomic Diagnostics for Intracranial Germ Cell Tumors |
Connecticut Children’s Medical Center Foundation, Inc. / Ching Lau, MD/PhD |
Reach Grants |
2021 |
Connecticut |
Astatine-211 Meta-Astatobenzylguanidine ([211At]MABG) Targeted Radiotherapy for Disseminated Neuroblastoma |
Children’s Hospital of Philadelphia / John Maris, MD |
Reach Grants |
2016 |
Pennsylvania |
Targeting PLK1 as a Common Mechanism in Ph-like ALL |
University of Texas M.D. Anderson Cancer Center / Joya Chandra, PhD |
Reach Grants |
2016 |
Texas |
Circumventing Pediatric Solid Tumor Microenvironment Resistance by Combinatorial CAR NK and Immunomodulating Therapy |
New York Medical College / Mitchell Cairo, MD |
Reach Grants |
2023 |
New York |
Feasibility Study of Dual Inhibition of MDM2 and Tubulin in Treatment of AML |
Emory University / Muxiang Zhou, MD |
Reach Grants |
2023 |
Georgia |
Targeting RNA Helicase DDX3 to Treat Recurrent High Grade Sarcoma
|
The Johns Hopkins University School of Medicine / David Loeb, MD, PhD |
Reach Grants |
2013 |
Maryland |